P G Claringbold

A phase I study of samarium-153 ethylenediaminetetramethylene phosphonate therapy for disseminated skeletal metastases.

J. Harvey Turner, P G Claringbold, E.L.R. Hetherington et al. · Journal of Clinical Oncology · 1989 · 135 citations

Surgical Oncology, Spinal Oncology, Orthopaedic Surgery +18

A kit formulation for the preparation of 188Re-lipiodol: preclinical studies and preliminary therapeutic evaluation in patients with unresectable hepatocellular carcinoma

Alessandra Boschi, Licia Uccelli, Adriano Duatti et al. · Nuclear Medicine Communications · 2004 · 55 citations

Pharmaceutical Science, Bioorganic Chemistry, Preliminary Therapeutic Evaluation +23

166Ho-microsphere liver radiotherapy

J. Harvey Turner, P G Claringbold, P. Klemp et al. · Nuclear Medicine Communications · 1994 · 48 citations

Radiopharmaceutical Therapy of 5T33 Murine Myeloma by Sequential Treatment With Samarium-153 Ethylenediaminetetramethylene Phosphonate, Melphalan, and Bone Marrow Transplantation

J. Harvey Turner, P G Claringbold, Linda Shapiro Manning et al. · JNCI Journal of the National Cancer Institute · 1993 · 23 citations

153Sm-EDTMP and melphalan chemoradiotherapy regimen for bone marrow ablation prior to marrow transplantation

Jennifer Turner, P G Claringbold, J. D. Berger et al. · Nuclear Medicine Communications · 1992 · 19 citations